ATLANTA—Diabetes has no influence on intravesical botulinum toxin type A (BoNTA) injection in overactive bladder (OAB) patients, researchers reported at the American Urological Association 2012 annual meeting.
In addition, OAB patients with diabetes mellitus (DM) have a significantly higher incidence of large post-voiding residuals and general weakness than non-diabetic patients.
Taiwanese researchers Chung-Cheng Wang, MD, and Hann-Chorng Kuo, MD, identified 217 patients who had received BoNTA injections, 48 of whom had DM. Videourodynamics were performed at baseline and repeated at three months after intravesical BoNTA injection.
Upon injection, diabetic OAB patients had a 60.4% rate of post-voiding residuals whereas non-diabetic OAB patients had a rate of 33.3% as well as a higher incidence of general weakness (10.4% vs. 0%). No major complications were observed in either group. Baseline urodynamic parameters could not account for adverse effects in diabetic patients.
“BoNTA injection was a safe and effective treatment for patients with OAB and diabetes,” the researchers concluded.